Key result
Low-dose rivaroxaban was associated with a reduced risk of stroke or systemic embolism compared with warfarin in Asian patients with atrial fibrillation (HR 0.76; 95% CI 0.70-0.84).
Why the study?
Low-dose prescription of rivaroxaban is common among Asian patients with AF, but its benefits and harms in this population remained unclear.
Does low-dose rivaroxaban reduce stroke/systemic embolism and bleeding compared to warfarin in Asian patients with atrial fibrillation?
Meta-Analysis (n=292,815)
Yes
Does low-dose rivaroxaban reduce stroke/systemic embolism and bleeding compared to warfarin in Asian patients with atrial fibrillation?
Hazard Ratio: 0.76 (95% CI 0.7–0.84)
Low-dose rivaroxaban (10-15 mg daily) is associated with reduced risks of stroke/systemic embolism and major bleeding compared to warfarin in Asian patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
May support low-dose rivaroxaban for stroke prevention in Asian AF; extends observational data but leaves bleeding and RCTs open.
Qian et al. (2021) conducted a meta-analysis in Atrial Fibrillation (n=292,815). Low-dose rivaroxaban vs. Warfarin was evaluated on stroke/systemic embolism (HR 0.76, 95% CI 0.70-0.84). Low-dose rivaroxaban was associated with a reduced risk of stroke or systemic embolism compared with warfarin in Asian patients with atrial fibrillation (HR 0.76; 95% CI 0.70-0.84).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: